Uveitis and Ocular Inflammation

Uveitis is a potentially sight-threatening form of ocular inflammation that demands precise diagnosis and management. As a future physician, understanding uveitis is crucial because it sits at the intersection of ophthalmology, rheumatology, and infectious disease, often serving as a window to systemic illness. Failure to recognize its signs or adequately control inflammation can lead to irreversible vision loss from complications like glaucoma, cataract, and macular edema.

Anatomy and Classification of Uveitis

To diagnose uveitis accurately, you must first understand the anatomy of the uvea. The uvea is the middle vascular layer of the eye, comprised of the iris (anterior), the ciliary body (intermediate), and the choroid (posterior). Uveitis is broadly defined as inflammation of any part of this uveal tract, but it frequently involves adjacent structures like the retina and vitreous.

The Standardization of Uveitis Nomenclature (SUN) Working Group classifies uveitis by two primary axes: anatomic location and chronicity. Anatomic classification is the cornerstone of the diagnostic approach:

• Anterior uveitis: Inflammation of the iris (iritis) and/or ciliary body (iridocyclitis). This is the most common form.
• Intermediate uveitis: Inflammation primarily in the vitreous (vitritis) and pars plana.
• Posterior uveitis: Inflammation of the choroid (choroiditis), retina (retinitis), or retinal vessels (vasculitis).
• Panuveitis: Inflammation involving all major segments of the eye.

Chronicity describes the disease course: acute (sudden onset and limited duration), recurrent (repeated episodes separated by periods of inactivity without treatment), or chronic (persistent inflammation with relapse in less than 3 months after discontinuing therapy). This classification immediately guides the urgency of workup and the likely etiologic suspects.

Clinical Presentation: Anterior vs. Posterior

The patient's symptoms and signs are direct reflections of the anatomic site of inflammation. Anterior uveitis typically presents with acute onset of eye pain, redness (conjunctival injection, especially around the cornea in a "ciliary flush"), photophobia (light sensitivity), and blurred vision. On examination, you will see cells (inflammatory white blood cells) and flare (increased protein) in the anterior chamber, often with keratic precipitates (clumps of cells) on the corneal endothelium.

In contrast, posterior uveitis is often less painful but more insidiously threatening to vision. Patients complain of floaters, blurred vision, or scotomata (blind spots). The redness may be minimal or absent. The true threat to vision comes from structural complications: macular edema (fluid accumulation in the central retina) is a leading cause of vision loss, and retinal vasculitis (inflammation of retinal blood vessels) can cause ischemia, hemorrhage, and neovascularization. Imagine a patient presenting with painless, progressive vision loss and countless floaters; your immediate concern must shift to the posterior segment.

Systematic Diagnostic Workup

Uveitis is not a final diagnosis but a clinical sign. Your task is to identify the underlying etiology, which broadly falls into infectious, autoimmune, masquerade (e.g., lymphoma), or isolated ocular conditions. A targeted workup is essential. For a young adult with acute anterior uveitis and a history of low back pain, you would prioritize testing for HLA-B27-associated conditions like ankylosing spondylitis. For a patient with bilateral posterior uveitis and neurological symptoms, you must consider sarcoidosis or a primary intraocular lymphoma.

The workup is heavily guided by the anatomic type. Anterior uveitis is often associated with HLA-B27 spondyloarthropathies or is idiopathic. Posterior or panuveitis raises a much broader differential, including infections like toxoplasmosis, syphilis, tuberculosis (TB), and herpes viruses, as well as autoimmune diseases like Behçet's disease or Vogt-Koyanagi-Harada syndrome. A systematic approach involves a detailed review of systems, targeted serology (e.g., syphilis RPR/FTA-ABS, quantiferon Gold for TB, HLA-B27), and often imaging like ocular coherence tomography (OCT) to assess for macular edema or fluorescein angiography to evaluate retinal vasculitis.

Treatment Principles and Immunosuppression

The primary goals of treatment are to relieve pain, preserve vision, and prevent complications. Corticosteroids are the mainstay for initial control of inflammation. They can be administered topically (e.g., prednisolone acetate drops for anterior disease), via periocular injection (for intermediate or posterior inflammation), systemically (orally or intravenously), or through intravitreal implants. The route is selected based on the location and severity of inflammation.

However, long-term reliance on corticosteroids, especially systemic ones, leads to unacceptable side effects like glaucoma, cataract, hyperglycemia, and osteoporosis. This necessitates the use of steroid-sparing immunosuppression to maintain long-term remission. These agents allow for the tapering and discontinuation of corticosteroids. Common steroid-sparing drugs include antimetabolites (methotrexate, mycophenolate mofetil), T-cell inhibitors (cyclosporine, tacrolimus), and biologics (anti-TNF agents like adalimumab, which is FDA-approved for non-infectious uveitis). The choice of agent depends on the specific etiology, patient comorbidities, and fertility considerations. For infectious uveitis (e.g., herpetic, toxoplasmic), specific antiviral or antibiotic therapy is paramount, often with cautious adjunctive corticosteroids to control destructive immune response.

Common Pitfalls

1. Treating without a diagnosis: Initiating corticosteroids for a presumed autoimmune uveitis without ruling out infection (like herpes or syphilis) can be disastrous, as steroids can cause an infection to proliferate uncontrollably. Always consider and rule out infectious mimics before starting immunosuppression.
2. Insufficient workup for posterior disease: Dismissing posterior uveitis as "idiopathic" without a thorough systemic evaluation can miss treatable infections or life-threatening systemic autoimmune diseases. A patient with retinal vasculitis may have undiagnosed Behçet's disease or sarcoidosis.
3. Over-reliance on topical steroids for posterior inflammation: Topical steroid drops cannot penetrate effectively to the posterior segment. Using them as the sole treatment for posterior uveitis allows the vision-threatening inflammation to progress unchecked while exposing the eye to steroid-induced cataract and glaucoma.
4. Delaying steroid-sparing therapy: Persisting with long-term moderate or high-dose oral steroids to control chronic uveitis, rather than promptly introducing a steroid-sparing agent, subjects the patient to systemic toxicity. The transition to maintenance immunosuppression should be planned early in the disease course.

Summary

• Uveitis is inflammation of the eye's uveal tract and is classified by its anatomic location (anterior, intermediate, posterior, panuveitis) and chronicity, which guides the diagnostic approach.
• Anterior uveitis commonly presents with acute pain, redness, and photophobia, while posterior uveitis is often less painful but threatens vision through complications like macular edema and retinal vasculitis.
• A systematic workup is mandatory to identify the underlying cause, aggressively ruling out infectious etiologies before attributing inflammation to autoimmune or idiopathic causes.
• Corticosteroids in various formulations are used to achieve rapid initial control of inflammation, but steroid-sparing immunosuppressive agents are critical for maintaining long-term remission and avoiding the systemic and ocular side effects of chronic steroid use.